The Effect of Electroacupuncture on Obesity

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Kyunghee University Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Kyunghee University Medical Center
ClinicalTrials.gov Identifier:
NCT01102075
First received: April 6, 2010
Last updated: April 9, 2010
Last verified: September 2009

April 6, 2010
April 9, 2010
January 2010
May 2010   (final data collection date for primary outcome measure)
waist circumference [ Time Frame: At 5 weeks (post treatment) ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01102075 on ClinicalTrials.gov Archive Site
  • Thickness of abdominal subcutaneous fat [ Time Frame: Study Day 1 (Baseline) ] [ Designated as safety issue: Yes ]
    Thickness of abdominal subcutaneous fat was measured by digital skinfold caliper(FatTrack).
  • Thickness of abdominal subcutaneous fat [ Time Frame: At 3weeks ] [ Designated as safety issue: Yes ]
    Thickness of abdominal subcutaneous fat was measured by digital skinfold caliper(FatTrack).
  • Thickness of abdominal subcutaneous fat [ Time Frame: At 5weeks (post treatment) ] [ Designated as safety issue: Yes ]
    Thickness of abdominal subcutaneous fat was measured by digital skinfold caliper(FatTrack).
  • Thickness of abdominal subcutaneous fat [ Time Frame: At 8weeks after first treatment (follow up) ] [ Designated as safety issue: Yes ]
    Thickness of abdominal subcutaneous fat was measured by digital skinfold caliper(FatTrack).
  • Waist hip ratio [ Time Frame: Study Day 1 (Baseline) ] [ Designated as safety issue: Yes ]
  • Waist hip ratio [ Time Frame: At 3weeks ] [ Designated as safety issue: Yes ]
  • Waist hip ratio [ Time Frame: At 5weeks (post treatment) ] [ Designated as safety issue: Yes ]
  • Waist hip ratio [ Time Frame: At 8weeks after first treatment (follow up) ] [ Designated as safety issue: Yes ]
  • Body Mass Index [ Time Frame: Study Day 1 (Baseline) ] [ Designated as safety issue: Yes ]
    Body Mass Index was measured by Inbody 720
  • Body Mass Index [ Time Frame: At 3weeks ] [ Designated as safety issue: Yes ]
    Body Mass Index was measured by Inbody 720
  • Body Mass Index [ Time Frame: At 5weeks (post treatment) ] [ Designated as safety issue: Yes ]
    Body Mass Index was measured by Inbody 720
  • Body Mass Index [ Time Frame: At 8weeks after first treatment (follow up) ] [ Designated as safety issue: Yes ]
    Body Mass Index was measured by Inbody 720
  • Body fat ratio [ Time Frame: Study Day 1 (Baseline) ] [ Designated as safety issue: Yes ]
    Body fat ratio was measured by Inbody 720
  • Body fat ratio [ Time Frame: At 3weeks ] [ Designated as safety issue: Yes ]
    Body fat ratio was measured by Inbody 720
  • Body fat ratio [ Time Frame: At 5weeks (post treatment) ] [ Designated as safety issue: Yes ]
    Body fat ratio was measured by Inbody 720
  • Body fat ratio [ Time Frame: At 8weeks after first treatment (follow up) ] [ Designated as safety issue: Yes ]
    Body fat ratio was measured by Inbody 720
  • Visceral Fat Area [ Time Frame: Study Day 1 (Baseline) ] [ Designated as safety issue: Yes ]
    Visceral Fat Area was measured by Inbody 720
  • Visceral Fat Area [ Time Frame: At 3weeks ] [ Designated as safety issue: Yes ]
    Visceral Fat Area was measured by Inbody 720
  • Visceral Fat Area [ Time Frame: At 5weeks (post treatment) ] [ Designated as safety issue: Yes ]
    Visceral Fat Area was measured by Inbody 720
  • Visceral Fat Area [ Time Frame: At 8weeks after first treatment (follow up) ] [ Designated as safety issue: Yes ]
    Visceral Fat Area was measured by Inbody 720
  • Body weight [ Time Frame: Study Day 1 (Baseline) ] [ Designated as safety issue: Yes ]
    Body weight was measured by Inbody 720
  • Body weight [ Time Frame: At 3weeks ] [ Designated as safety issue: Yes ]
    Body weight was measured by Inbody 720
  • Body weight [ Time Frame: At 5weeks (post treatment) ] [ Designated as safety issue: Yes ]
    Body weight was measured by Inbody 720
  • Body weight [ Time Frame: At 8weeks after first treatment (follow up) ] [ Designated as safety issue: Yes ]
    Body weight was measured by Inbody 720
  • Obesity degree [ Time Frame: Study Day 1 (Baseline) ] [ Designated as safety issue: Yes ]
    Obesity degree was measured by Inbody 720
  • Obesity degree [ Time Frame: At 3weeks ] [ Designated as safety issue: Yes ]
    Obesity degree was measured by Inbody 720
  • Obesity degree [ Time Frame: At 5weeks (post treatment) ] [ Designated as safety issue: Yes ]
    Obesity degree was measured by Inbody 720
  • Obesity degree [ Time Frame: At 8weeks after first treatment (follow up) ] [ Designated as safety issue: Yes ]
    Obesity degree was measured by Inbody 720
  • Bulimia Test Revised [ Time Frame: Study Day 1 (Baseline) ] [ Designated as safety issue: Yes ]
  • Bulimia Test Revised [ Time Frame: At 5weeks (post treatment) ] [ Designated as safety issue: Yes ]
  • Korean version of Obesity-related QOL scale [ Time Frame: Study Day 1 (Baseline) ] [ Designated as safety issue: Yes ]
  • Korean version of Obesity-related QOL scale [ Time Frame: At 5weeks (post treatment) ] [ Designated as safety issue: Yes ]
  • Body Shape Questionnaire [ Time Frame: Study Day 1 (Baseline) ] [ Designated as safety issue: Yes ]
  • Body Shape Questionnaire [ Time Frame: At 5weeks (post treatment) ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
The Effect of Electroacupuncture on Obesity
The Effect of Low Frequency Electroacupuncture on Waist Circumference in Obesity-Three Arm Randomized Controlled Trial, Pilot Study

The purpose of this study is to determine whether electroacupuncture is effective on waist circumference in obesity.

Many studies have reported on the beneficial effects of acupuncture for obesity, although some negative reports also existed.(Wang F. et al. 2008)Recently conducted systematic review of Pittler and Ernst reported that there was insufficient, but not conclusive evidence to support the efficacy of acupuncture and acupressure for weight loss. However, most of these studies had methodological limitation, such as lack of adequate control group or unclear specific effect of electroacupuncture alone because auricular acupuncture was administered as well. In this sudy, we had three-arm randomized controlled trial(with sham control group) to investigate whether electroacupuncture is effective in the treatment of obesity.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Obesity
  • Device: Electroacupuncture
    We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)
    Other Name: EA group
  • Device: Sham electroacupuncture procedure
    We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
    Other Name: Sham EA group
  • Experimental: Electroacupuncture
    The Electroacupuncture therapy protocol included a total of 12 acupuncture points at the CV12,CV6, bilateral ST25, SP15, SP14,LI4, LI11, ST36, ST44. All acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Abdominal acupuncture points were inserted horizontally 6~6.5cm in depth and the others were inserted vertically 2~2.5cm in depth until patient can feel De-Qi. All acupuncture points were stimulated electrically with a frequency of 24 Hz an intensity of 0.27-1.3mA(tolerable strength) with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks by practitioner who had had 6 years of acupuncture training and 3 more years of clinical experience.
    Intervention: Device: Electroacupuncture
  • Sham Comparator: Sham electroacupuncture procedure
    The Sham electroacupuncture therapy protocol(Non-acupoint, No electrical stimulation)included the same number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment, but superficially at non acupuncture points 15 mm to the lateral of each acupuncture point was treated. The points were not stimulated electrically, but the sound of the pulse generator was heard by the participants. (Lee SH, LeeBC 2009) Those receiving EA or SEA therapy were treated on alternate days to prevent crosstalk among groups, which could have compromised the blinded study design.
    Intervention: Device: Sham electroacupuncture procedure
  • No Intervention: Waiting list
    No treatment was done for waiting group, but could receive same treatments as Electroacupuncture group after the end of trial.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
39
May 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Waist circumference: Male>= 90 cm, Female >= 85 cm
  • BMI over than 25kg/m2

Exclusion Criteria:

  • Secondary obesity caused by endocrine disease, e.g., polycystic ovary syndrome, diabetes mellitus, Cushing's syndrome, hypothyroidism etc.
  • Heart disease,e.g.,arrhythmia, heart failure, myocardial infarction, and patient with pacemaker
  • Hypertension, hyperlipidemia or hypercholesterinemia patients on medication
  • Stroke or otherwise unable to exercise
  • Pregnant or lactating women
  • Childbirth within 6 months
  • Management for weight control within 3 months
  • Any other conditions deemed unsuitable for trial as evaluated by the physician-in-charge
Both
16 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01102075
KOMC MIRB 2009-6
Yes
Sung Keel Kang, Kyunghee University Medical Center
Kyunghee University Medical Center
Not Provided
Principal Investigator: Sung Keel Kang, Doctor Kyunghee University Medical Center Oriental Hospital
Kyunghee University Medical Center
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP